The Indonesian HTA Committee (InaHTAC) was formally renewed and continues its work as a facilitator of national HTA studies as of 2016. Under their oversight, three HTA economic evaluation studies were completed from 2014-2016: the economic evaluation of sildenafil as a first line treatment for pulm

The iDSI Indonesia project aims to institutionalize Health Technology Assessment in the country, to improve health system efficiency, and to prioritize interventions to ensure the longevity of the Universal Health Coverage Scheme or the Jaminan Kesehatan Nasional (JKN). In continuing support toward

The Health Intervention and Technology Assessment Program (HITAP), Ministry of Public Health, Thailand, has been working with the Health Technology Assessment Committee (HTAC), Ministry of Health, Indonesia, since 2014 under the auspices of the International Decision Support Initiative (iDSI). Si

EXECUTIVE SUMMARY  The Health Intervention and Technology Assessment Program Foundation (HITAP), Thailand, undertook a mission to Colombo, Sri Lanka, supported by the World Bank Group. The mission aimed to support national efforts to strengthen capacity on health priority setting and institutiona

The report summarises a visit to Tanzania and has been prepared by Mr. Panupong Chaowanasawat and Dr. Brandon Chua from the Health Intervention and Technology Assessment Program Foundation (HITAP), Thailand. The study visit was supported by the Access and Delivery Partnership (ADP), led by the Unite

Antimicrobial resistance (AMR) is a global public health challenge that affects human health, animal health and the environment. It also threatens the national economy through food exports and medical tourism. Thailand’s Second National Action Plan on AMR sets six goals and six strategies under a One Health approach. The Thai Food and Drug Admini

During May 2010 to March 2011, a feasibility study of the community health initiative for MCH care was conducted in the Lewe, Yedarshey and Tatkone Townships by HITAP, the WHO and the MoH, Myanmar. The first study mission in May 2010 developed a protocol for the community health initiative whi

Abstract Surrogate endpoints are frequently used as primary outcomes in clinical trials. This is appropriate when they are validated for their ability to predict clinical benefit measured on patient-relevant target outcome(s). Such validation is often lacking, thus increasing uncertainty in the dec